drugset
drugset / Trial / NCT05487404

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

NCT05487404 ↗

Phase 1/2 Completed 26 enrolled Aldeyra Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

A Double-Blind Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol Levels

Timeline

Start
2021-11-15
Primary completion
2022-05-29
Completion
2022-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject ACLOPROXALAP Other / unclassified 600 mg Oral

Indications

poisoning